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Original article 1Endovascular treatment of chronic cerebro spinal venous
insufficiency in patients with multiple sclerosis modifies
circulating markers of endothelial dysfunction and
coagulation activation: a prospective study
Mariasanta Napolitanoa, Aldo Brunob, Diego Mastrangelob, Marcella De Viziab,
Benedetto Bernardob, RosaBuonagura c and Domenico De LuciadObjectives We have performed a monocentric
observational prospective study to evaluate coagulation
activation and endothelial dysfunction parameters in
patients with multiple sclerosis undergoing endovascular
treatment for cerebro-spinal-venous insufficiency.
Materials and methods Between February 2011 and July
2012, 144 endovascular procedures in 110 patients with
multiple sclerosis and chronical cerebro spinal venous
insufficiency were performed and they were prospectively
analyzed. Each patient was included in the study according
to previously published criteria, assessed by the
investigators before enrollment. Endothelial dysfunction
and coagulation activation parameters were determined
before the procedure and during follow-up at 1, 3, 6, 9, 12, 15
and 18 months after treatment, respectively. After the
endovascular procedure, patients were treated with
standard therapies, with the addition of mesoglycan.
Results Fifty-five per cent patients experienced a favorable
outcome of multiple sclerosis within 1 month after
treatment, 25% regressed in the following 3 months, 24.9%
did not experience any benefit. In only 0.1% patients, acute
recurrence was observed and it was treated with high-dose
immunosuppressive therapy. No major complications were
observed. Coagulation activation and endothelial
dysfunction parameters were shown to be reduced at 10957-5235  2014 Wolters Kluwer Health | Lippincott Williams & Wilkinsmonth and stable up to12-month follow-up, and they were
furthermore associated with a good clinical outcome.
Conclusions Endovascular procedures performed by a
qualified staff are well tolerated; they can be associatedwith
other currently adopted treatments. Correlations between
inflammation, coagulation activation and
neurodegenerative disorders are here supported by the
observed variations in plasma levels of markers of
coagulation activation and endothelial dysfunction. Blood
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Multiple sclerosis is a demyelinating disease, which
affects approximately 1/1000 of the general population;
it has an incidence of approximately 60 000 patients in
Italy [1–4]. Multiple sclerosis is a chronic disease charac-
terized by inflammatory lesions with multifocal modifi-
cation of the coating honey-like state of neurons and
subsequent axonal degeneration [2,4–6]. In 2006, it was
observed that patients with multiple sclerosis suffered
also cerebral and vertebral veins insufficiency; this
phenomenon was associated to a slower blood flow with
consequent development of collateral veins [7]. The
disease was identified with the acronym CCSVI (chronic
cerebro spinal venous insufficiency).
Vascular abnormalities, slowing venous outflow, can
affect, especially in the brain, the expression of adhesion
molecules by the cerebrovascular endothelium, leadingto an increased permeability of the blood–brain barrier.
Increased vascular permeability is associated with inflam-
mation because of the secretion of pro-inflammatory
cytokines from activated endothelial cells. During this
process, monocytes have been shown to initiate an auto-
immune process against myelin-containing cells [7–13].
Several methods have been evaluated for the diagnosis of
CCSVI, and among them, the most suitable for the type
of vessels and blood flow has been considered echo-
Doppler (ECD), with a specific equipment for slow flows
and integrated transcranial Doppler (TCCS).
ECD-TCCS allows the assessment of deep cerebral veins
and the detection of any venous reflux [3,10,14–18]. A
new access in the ultrasonography evaluation of deep
venous cerebral vasculature through the meat of
Rosenthal has been recently adopted [18,19]. The sameDOI:10.1097/MBC.0000000000000132
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the diagnosis of CCSVI [18,20].
Activation of coagulation with fibrin deposition has been
observed in central nervous system (CNS) blood vessels
in animal model of multiple sclerosis [21,22]; growing
evidences correlate activation of coagulation to inflam-
matory disease of CNS [21–23].
We have determined coagulation parameters and markers
of endothelial dysfunction to monitor their variations
after endovascular treatment of CCSVI.
We here report the results of a prospective study in which
patients undergoing endovascular treatment for CCSVI
have been evaluated with clinical, instrumental and
laboratory determinations before and up to 18 months
after the procedure.
Materials
A total of 110 patients were enrolled in this study, from
February 2011 to July 2012: 75 females, 35 males (age
range: 25–72 years). They all had a definite diagnosis of
multiple sclerosis: 23 patients were suffering from a
progressive primary-type multiple sclerosis, 32 from
relapsing/remitting multiple sclerosis and 55 from a sec-
ondary progressive form of multiple sclerosis. Enrolled
patients came from all regions of Italy.
Patients treated with immunomodulatory drugs (inter-
feron or glatiramer acetate) were 78% of total, 15%
patients were receiving immunosuppressive therapy,
and the remaining 7% were off-therapy at study entry.
A total of 144 endovascular procedures were performed.
Observation period lasted 12 months in 84 patients and
18 months in 60 patients. Clinical follow-up visits aimed
to evaluate the incidence of relapse of multiple sclerosis
after endovascular treatment. Patients were regularly
followed-up after the procedure at the same institution
where the procedure was performed (Clinica Gepos).
Informed consent was obtained from each patient
enrolled in the current study.
Patients preliminarily underwent ECD-TCCS for
CCSVI diagnosis; the examination was always repeated
before endovascular treatment, in order to confirm that
there were prerequisites for an abnormal discharge of
venous vessels (vertebral, jugular veins and deep cerebral
veins) of the neck.
ECD-TCCS parameters evaluated are as follows:(1) Bidirectional flow in one or both of the internal
jugular vein (IJV) and/or vertebral vein in both
positions or two-way flow in a location with no flow in
the other(2) Bidirectional flow in intracranial veins and sinuses
(3) Intraluminal defect (flaps, valves or septa) associ-
ated with hemodynamic changes (blocks, reflux oracceleration) and/or decreased in IJV in supine
position to 0.3 cm/q(4) No flow in IJV and/or vertebral vein and/or no bi-
directional flow in one flow and position flow in
the other(5) dCSA IJV greater than or unchanged both at 90 and
0 degree.The procedure was performed only by expert physicians,
when at least two of the criteria for a diagnosis of CCSVI
were satisfied [18,20].
Expanded disability status scale (EDSS) was adopted in
the evaluation of the clinical picture and of any existing
disability [6]. Benefits deriving from endovascular treat-
ment were defined as the disappearance and/or reduction
of neurological symptoms with a reduction of at least 0.5
points in EDSS score.
Relapses were defined as the appearance of a new neuro-
logical symptom or its deterioration with an increase of at
least 0.5 point in EDSS score [24]. EDSS score was
calculated by a neurologist the day after endovascular
treatment and during follow-up.
EDSS evaluation was based on the following parameters:
pyramidal disorder (gait); cerebellar disorders (coordina-
tion); cerebral disorders (abnormalities in speech and
swallowing); sensorial disorders (abnormal sensations
and painful symptoms); bladder and bowel disorders;
visual modifications; mental disorders; other (symptoms
attributable to multiple sclerosis.)
Endovascular procedure and treatment
The procedure was performed with a femoral access,
under local anesthesia with Lidocaine at 2%. The femoral
vein was identified on anatomical location or eco-led
sting. A short sheath (8 -9 F) was used.
Before the endovascular procedure, 2500 IU of Sodium
Heparin were administered. A guidewire 260-cm long,
stiff type (Acquatack; Cordis Corporation, Warren, New
Jersey, USA), was used in association with 100 from Ber
4F Catheters for jugular veins and Cobra 4F Catheters for
azygos veins. Lesions of azygos veins were treated with
balloons (Cordis) measuring 8–10 mm in diameter and
4 cm in length, with a pressure from 8 to 10 atm for 120 s.
Lesions of the jugular veins were treated with 10–20
balloons of Cordis with low-compliance chart and a
compression between 4 and 8 atm for 120 sec. In the
case of hypoplasia of the jugular vein, balloons sized
12–10 mm in diameter were adopted. Hemostasis was
achieved with compression.
All patients were discharged on the first day after the
procedure. Therapy with low-molecular-weight heparin
(LMWH) was started in the evening of the procedure and
continued for 20 days after endovascular treatment, at a
therapeutic dosage. Following LMWH therapy, the use
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Table 1 Demographic and clinical data
Variables (range) Males, n¼35 Females, n¼75
Age (years) 40 (28–72) 32 (25–63)
BMI (kg/m2) 22 (19.1–30.8) 21 (18–27)
% of subjects
Smokers 27
Previous pregnancy 22.6
NSAID intake 26.2
Alcohol intake 35
NSAID, non steroidal anti-inflammatory drugs.of Mesoglycan at a daily dose of 100 mg was recom-
mended up to 24 months after endovascular treatment.
Laboratory assays
Laboratory parameters were first determined in each
patient before (from 1 week–1 month) endovascular
treatment and they were sequentially repeated during
follow-up visits at 1, 3, 6, 9, 12 and 18 months.
The following parameters were assessed: C-reactive
protein (CRP), fibrinogen (Fg), coagulation Factor X
(FX: c), activated coagulation factor X (FXa), prothrom-
bin fragment (F1þ2), homocysteine, tissue-plasminogen
activator (t-PA), plasminogen-activated inhibitor (PAI-1),
adhesion molecules [intercellular adhesion molecule 1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1)] and Von Willebrand factor antigen (VWF: Ag). All
tests were assayed following methods recognized by
international guidelines. CRP was determined with an
immunoturbidimetric method (Thermofisher, Fisher
Diagnostic, Illkirch Cedex - France); Fg plasma levels
were assayed by the Clauss functional method. The
measurement of factor X activity was performed by a
chromogenic method using an automated coagulometer
(ACL 2000; Instrumentation Laboratory, Milan, Italy).
FXa was determined with a chromogenic assay (Abcam
FXa kit Abcam plc, Cambridge, UK). F1þ2 were assayed
using an ELISA method (Enzygnost F1þ2; Behring,
Marburg, Germany). Homocysteine was assayed with
an automated immunologic method (Hemosil, Instru-
mantation of Laboratory). T-P and PAI-1 plasmatic anti-
gen levels were measured by enzyme-linked
immunosorbent assay (ELISA) (Bouty, Milan, Italy).
Circulating VCAM-1 and ICAM-1 concentrations were
measured by an immunoenzymatic method (R&D Sys-
tems, Minneapolis, Minnesota, USA). Plasma concen-
trations of VWF: Ag were measured with an ELISA
technique (Asserachrom vWF, Diagnostica Stago, Par-
sippany, New Jersey, USA).
Statistical analysis
The data description was based on standard measures of
the distribution, such as mean for the position parameter
and standard deviation (SD) for the variability. The
normality of the parameter distribution was evaluated
through the Kolmogorov Smirnov test. To evaluate
parameter linear relations, we also calculated Pearson
test and performed regression analysis. To compare
median values of different groups, we used the Krus-
kal–Wallis test when the normality was rejected. Differ-
ences were tested with Bonferroni correction at the
P< 0.05 significance level. Laboratory data that could
be expressed in means are shown as meansSD. All
statistical levels quoted are two-tailed. Correlation
analysis between sets of data was performed. Where
useful, the confidence interval (CI) of the test value
and the P value were provided. Analyses were conductedusing the medical software version 7.4.1.2 (http:
www.medcalc.be).
This study protocol was approved by the institutional
review boards (IRB) of GEPOS Clinic and Second Uni-
versity of Naples. The study has been performed in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
Results
General demographic data of the patient cohort are
shown in Table 1.
Response to treatment was observed in 110 patients after
the first endovascular treatment, whereas in 34 cases,
endovascular treatment procedure was repeated because
of recurrence. Major complications, morbidity and/or
disability secondary to endovascular treatment, were
not observed. In only two cases, a minor complication
(self-limiting inguinal hematoma) was observed; it did
not require a prolonged hospital staying. Endovascular
treatment procedure was successfully performed in 99%
of patients. In only two cases, it was not possible to
perform the procedure because of a pre-existing central
venous catheter thrombosis.
Clinical and instrumental evaluation
Endovascular procedure for CCSVI determined an
improvement of the following neurological symptoms:
weakness and paresthesia; functional capacity of arms
and legs (with cases of functional recovery immediately
after endovascular treatment); sphincter control; vision;
headache. There was a low incidence of recurrence
during the observation period. A very good correlation
(>90%) between ECD-TCCS with dedicated equipment
and flebography was observed.
Laboratory determinations
Main results related to laboratory assessment before and
after endovascular treatment are shown in Table 2.
Values are shown as mean 1 SD. The values reported
on the column post endovascular treatment refer to 1 and
12-month follow-up. Interestingly, a statistically signifi-
cant (P< 0.05) reduction in Fg, CRP, coagulation factor
X, F1þ2, homocysteine, VWF: Ag, t-PA, PAI-1, ICAM-1
and VCAM-1 plasma levels was observed at the first
follow-up visit (30 days after endovascular treatment).
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Table 2 Endothelial dysfunction and coagulation activation markers before and after endovascular treatment of CCSVI
Marker Controls (n¼200)
After endovascular
treatment (1 month)
(n¼110)
After endovascular
treatment (12 months)
(n¼110)
Before endovascular
treatment (n¼110) P value
Fg (mg/dL) 26475.5 350.557.5 42555.5 42555.5 0.43
Coagulation factor X (%) 12532.5 14535 13837 16537.5 0.26
FXa (mg/ml) 0.50.25 0.70.3 0.60.28 0.60.34 0.38
F1þ2 (nmol/l) 0.450.35 0.950.75 0.90.55 1.951.5 0.18
VWF: Ag (%) 14537.5 15547.3 14738.9 20055 <0.001
t-PA (ng/ml) 6.53.5 5.52.0 4.92.3 11.55.6 <0.001
PAI-1 (ng/ml) 3717.5 30.530.5 29.423.8 70.535.2 <0.001
Hcy (mmol/l) 8.54.2 12.53.5 11.93.7 15.01.7 0.03
CRP (mg/dl) 0.950.60 2.52.5 1.91.8 5.52.7 0.02
s-ICAM-1 (ng/ml) 15739 26560 26055 30562 0.115
s-VCAM-1 (ng/ml) 63799 75550.5 74063.5 85564 0.001
CRP, C-reactive protein; F1þ2, prothrombin fragment1þ2; Fg, fibrinogen; FXa, activated factor X; Hcy, homocysteine; PAI-1, plasminogen activated inhibitor; s-ICAM-1,
soluble intercellular adhesion molecule 1; s-VCAM-1, soluble vascular cell adhesion molecule-1; t-PA, tissue-plasminogen Activator; VWF: Ag, von Willebrand factor
antigen.All these parameters, compared with baseline, were
shown to be stably reduced during a 12-month follow-
up period (in particular, VWF: Ag: 200 55 vs.
147 38.9, P< 0.001; t-PA: 11.5 5.6 vs. 4 0.9 2.3,
P< 0.001; PAI-1: 70.5 35.2 vs. 29.4 23.8, P< 0.001),
and they were associated with a good clinical outcome. A
very good inverse correlation was furthermore observed
between F1þ2 and PAI-1 plasma levels (r¼ 0.69,
P¼ .007) and homocysteine and F1þ2 plasma levels.
Controls refer to a population of healthy subjects.
Discussion
Endovascular treatment of CCSVI with angioplasty has
been suggested to improve cerebral venous drainage,
with significant improvement of symptoms evaluated
with EDSS scale [6]. The reason why only some patients
respond to endovascular treatment is currently not well
understood [14,20]; certainly, a high proportion of
patients with multiple sclerosis has lesions of the jugular,
vertebral and azygos veins, with a braking in venous
outflow.
As regards relapses, they are most frequently recorded in
the first 6 months after the procedure, whereas their
incidence decreases in the following months. Medical
treatment with sodium heparin, LMWH and mesoglycan
after endovascular treatment seems to play an important
role in preventing re-occlusion but further ad-hoc studies
are needed to confirm this hypothesis.
CCSVI treatment offers new perspectives in treating
young patients with multiple sclerosis and a low quality
of life. The best results are usually obtained in patients
with relapsing/remitting multiple sclerosis or secondary
progressive multiple sclerosis, a recent diagnosis of dis-
ease and a light degree of disability [13,24]. Patients with
advanced illness, diagnosed from many years, have a
reduced or extremely modest benefit with a high fre-
quency of rest enosis. Some recent studies report discor-
dant results related to the clinical relevance of CCSVI
[25,26].Important variables limiting our study are the following:
subjectivity of the endovascular treatment procedure,
compliance to protocol indications and learning ability
of the researchers performing the procedure. Our results,
furthermore, derive from a monocentric study even if
enrolled patients came from different regions of Italy.
To the best of our knowledge, this is the first report to
correlate clinical benefits post endovascular treatment to
laboratory markers of endothelial dysfunction and coagu-
lation activation in patients with multiple sclerosis.
We evaluated variations in laboratory markers before and
after endovascular treatment and correlated them with
the clinical improvement of symptoms. In some cases, a
significant reduction of cerebral myelin degeneration was
observed after the procedure.
Our findings suggest that endovascular treatment is able to
restore a normal endothelial function (stably reduced
soluble adhesion molecules) and to control activation of
coagulation by reducing fibrinogen, F1þ2, coagulation
coagulation factor X plasma levels and inflammatory mar-
kers like CRP. These results have been observed 30 days
after endovascular treatment and they are stable during 12-
month follow-up, thus supporting the hypothesis that
vascular abnormalities with venous stasis could somehow
affect neurological performances of patients with multiple
sclerosis and CCSVI.
Our findings support the hypothesis that vascular
abnormalities with venous stasis can somehow affect
neurological performances of patients with multiple
sclerosis and CCSVI, they also suggest that coagulation
activation and endothelial dysfunction play a significant
role in multiple sclerosis and represent an interesting
target for future treatments. Endovascular treatment of
stenosis is able to restore a normal coagulation profile and
represents a valid therapeutic option.
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